Bayer Collaborates with Children’s Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia

 Bayer Collaborates with Children’s Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia

Bayer Collaborates with Children’s Hospital of Philadelphia to Develop Oral Non-Replacement Therapy for the Treatment of Hemophilia A and B

Shots:

  • Bayer to invest $5M in the three-year collaboration with an option to extend the collaboration, if agreed by both the companies. The companies will jointly develop a first-in-class oral small molecule-based NRT for the treatment of hemophilia A and B
  • Bayer to get an option to license the product developed under the collaboration. The agreement will integrate CHOP’s expertise in hemophilia and coagulation with Bayer’s research capabilities
  • The alliance has the potential to change the treatment paradigm for patients with hemophilia. Additionally, Bayer is currently working to develop gene therapy for hemophilia A patients which may reduce the frequency of treatment

Click here to­ read full press release/ article | Ref: Bayer | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post